GlobeNewswire All Public CompaniesCodex · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 08-24 20:00:00·⟳ 抓取 08-24 20:03:30·⚡ 决策 08-26 01:48:14 +1d05h·63.1 天前
Bionano宣布参加H.C. Wainwright全球投资会议
本次公告不包含新增订单、产品商业化、监管审批、融资或业绩变化，无法形成方向明确的正期望交易。
📄 原文GlobeNewswire All Public Companies↗ 原文
Bionano to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will…
不做 Bionano Genomics, Inc.（BNGO.US）
仅为例行投资者会议参与公告，无经营、资本结构或证券供需新增事实，缺乏可交易edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
GlobeNewswire原文和公开转载均显示，Bionano只是宣布参加2026年9月14日H.C. Wainwright全球投资会议并进行管理层交流；H.C. Wainwright会议官网确认该会议为常规投资者会议。该类公告本身不改变收入、利润、现金流、资本结构或上市证券供需，且Bionano过往也发布过类似年度会议出席公告，因此不对BNGO.US开仓。
消息传播链
- Bionano发布会议参与公告，未披露任何经营或资本市场新增事项。
- Yahoo转载同一GlobeNewswire稿件，没有新增事实。
主要风险
- 会议中未来可能披露新业务更新，但当前这条公告本身没有任何可交易增量。
- BNGO为小市值低价股，单日波动可能较大，但价格波动不能替代基本面催化。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-24 · 影响 invalidates
公开稿件未包含订单、融资、临床监管、业绩指引或商业化更新。
检索:Bionano H.C. Wainwright conference announcement order financing clinical approval guidance 原文 ↗ - 做空前查反向 · 来源 web · 日期 2026-08-24 · 影响 none
本事件也没有披露新增公司级净利空，不能作为做空催化。
检索:Bionano Genomics H.C. Wainwright conference announcement negative event 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例确认本次属于公司年度会议参与公告，进一步支持不做BNGO.US。
方向:相似材料支持这是例行IR曝光事件，本身不提供可交易方向。
涨幅量级:没有高相似且锚点干净的event_study样本可用于涨跌幅校准。
形态:缺少足够价格样本；但事件机制本身没有现金流或预期差。
历史先例(按相似度)
- 相似度 7/10 BNGO 2025-08-25 Bionano在2025年也宣布参加H.C. Wainwright第27届年度全球投资会议。 原文 ↗
事件后 +1日 +2.5% · +2日 -0.2% · +3日 -2.5% · +4日 -3.8% · +5日 -5.8%
⚠锚前1-2日已异动17.3%>锚定日2.5% — 该行涨幅别用来定止盈止损
相似度依据:同一公司、同一会议主办方、同类年度会议参与公告，但缺少可比事件研究价格测算。
经验:例行投资者会议参与公告通常只提供沟通渠道，不等同于经营催化。
原文全文
展开原文 · 1,691 字
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that management will present and host 1x1 meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026.
Conference & Webcast Details
| Date: | September 14, 2026 |
| Time: | 10:30 a.m. ET |
| Presenter: | Al Luderer, PhD, Chairman and Interim CEO of Bionano |
| Webcast: | Register Here |
A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 90 days.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for clinical, translational, medical, and basic research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit bionano.com or bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
CONTACTS
Company Contact:
Al Luderer, Chairman & Interim CEO
Bionano Genomics, Inc.
+1 (781) 507-4438
Aluderer@bionano.com
Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817
IR@bionano.com
Conference & Webcast Details
| Date: | September 14, 2026 |
| Time: | 10:30 a.m. ET |
| Presenter: | Al Luderer, PhD, Chairman and Interim CEO of Bionano |
| Webcast: | Register Here |
A replay / recording of the session will be available following the conference through the Bionano website at ir.bionano.com for at least 90 days.
About Bionano
Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for clinical, translational, medical, and basic research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.
For more information, visit bionano.com or bionanolaboratories.com.
Bionano’s products are for research use only and not for use in diagnostic procedures.
CONTACTS
Company Contact:
Al Luderer, Chairman & Interim CEO
Bionano Genomics, Inc.
+1 (781) 507-4438
Aluderer@bionano.com
Investor Relations:
Webb Campbell
Gilmartin Group
+1 (415) 520-5817
IR@bionano.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。